{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T12:04:00Z","timestamp":1795089840625,"version":"4.10.2"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Relapsed or refractory acute lymphoblastic leukemia poses a significant clinical challenge due to its poor prognosis, showing survival rates of less than a year even with the use of novel therapies. In this report, we describe the safe and effective use of trametinib combined with dasatinib in a patient with acute lymphoblastic leukemia (ALL). To the best of our knowledge, this is the first report on the successful use of 2 targeted drugs such as trametinib and dasatinib in a pediatric patient with Ph+ ALL and recurrent pancreatitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 6-year-old boy with ALL and Philadelphia chromosome (Ph+) who had recurrent asparaginase-associated pancreatitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>The patient was diagnosed with ALL, based on clinical features, laboratory analyses, bone marrow aspiration evaluation in morphology, immunology, cytogenetics, and molecular.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient was treated with dasatinib combined with an intermediate risk-oriented chemotherapy. However, owing to recurrent asparaginase-associated pancreatitis, the patient has to abandon asparaginase in consolidation. Considering the high risk of relapse, we used trametinib and dasatinib combined with chemotherapy as maintenance chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After 6 months, there were no obvious side effects or residual disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>We suggest that the combination of trametinib and dasatinib may represent a viable option to treat patients with potential relapsed\/refractory Ph+ ALL.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026440","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T13:35:51Z","timestamp":1624455351000},"page":"e26440","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-4749","authenticated-orcid":false,"given":"Jing","family":"Wang","sequence":"first","affiliation":[{"name":"Ningbo Women and Children's Hospital, Ningbo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Hong","family":"Shen","sequence":"additional","affiliation":[{"name":"Shanghai Children's Medical Center, Shanghai Jiaotong University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin-Fei","family":"Hu","sequence":"additional","affiliation":[{"name":"Ningbo Women and Children's Hospital, Ningbo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan-Ling","family":"Wang","sequence":"additional","affiliation":[{"name":"Ningbo Women and Children's Hospital, Ningbo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jamaoncol.2019.5868","article-title":"Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"6","author":"Shen","year":"2020","journal-title":"JAMA Oncol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.19.02208","article-title":"Asparaginase-associated pancreatitis in acute lymphoblastic leukemia: results from the NOPHO ALL2008 treatment of patients 1-45\u200ayears of age","volume":"38","author":"Rank","year":"2020","journal-title":"J Clin Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1182\/blood-2015-04-639138","article-title":"MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia","volume":"126","author":"Jones","year":"2015","journal-title":"Blood"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/leu.2016.203","article-title":"Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol","volume":"31","author":"Wolthers","year":"2017","journal-title":"Leukemia"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1200\/JCO.2015.64.5812","article-title":"Clinical and genetic risk factors for acute pancreatitis in patients with acute lymphoblastic leukemia","volume":"34","author":"Liu","year":"2016","journal-title":"J Clin Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","article-title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia (DFCI 05-001): a randomized, open-label phase 3 trial","volume":"16","author":"Place","year":"2015","journal-title":"Lancet Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/pbc.22076","article-title":"Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis","volume":"53","author":"Kearney","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1182\/blood.V122.21.3915.3915","article-title":"The number of PEG-asparaginase doses administered is a determinant of relapse risk in adult ALL treated with a pediatric-like regimen","volume":"122","author":"Aldoss","year":"2013","journal-title":"Blood"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S1470-2045(17)30424-2","article-title":"Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study","volume":"18","author":"Wolthers","year":"2017","journal-title":"Lancet Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2018-08-832105","article-title":"How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"133","author":"Ravandi","year":"2019","journal-title":"Blood"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ccr.2011.11.004","article-title":"Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia","volume":"20","author":"Packer","year":"2011","journal-title":"Cancer Cell"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.3324\/haematol.2017.174060","article-title":"Trametinib inhibits RAS-mutant MLL-rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in vivo","volume":"103","author":"Kerstjens","year":"2018","journal-title":"Haematologica"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.leukres.2007.09.017","article-title":"Blockade of MEK\/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene","volume":"32","author":"Nishioka","year":"2008","journal-title":"Leuk Res"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1158\/0008-5472.CAN-16-2593","article-title":"Adaptation to TKI treatment reactivates ERK signaling in tyrosine kinase-driven leukemias and other malignancies","volume":"77","author":"Bruner","year":"2017","journal-title":"Cancer Res"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1182\/blood.V94.4.1209","article-title":"Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia","volume":"94","author":"D\u00f6rdelmann","year":"1999","journal-title":"Blood"},{"key":"R16-20250504","first-page":"2730","article-title":"Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome","volume":"92","author":"Schrappe","year":"1998","journal-title":"Blood"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1158\/0008-5472.CAN-15-1580","article-title":"The dual MEK\/FLT3 inhibitor E6201 exerts cytotoxic activity against acute myeloid leukemia cells harboring resistance-conferring FLT3 mutations","volume":"76","author":"Zhang","year":"2016","journal-title":"Cancer Res"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1177\/2472555220924478","article-title":"Identification of a triple drug combination that is synergistically cytotoxic for triple-negative breast cancer cells using a novel combination discovery approach","volume":"25","author":"Ahmad","year":"2020","journal-title":"SLAS Discov"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:05:05Z","timestamp":1746338705000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026440"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":18,"journal-issue":{"issue":"25","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026440","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]},"assertion":[{"value":"2021-04-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}